98%
921
2 minutes
20
Objective: To assess the ability of a zero-echo time sequence combined with a highly flexible adaptive image receiving coil (AIRTM coil) to visualize pulmonary neoplasms.
Methods: A total of 42 patients with pulmonary neoplasms were included, all of whom underwent chest CT and MRI examinations. A highly flexible AIRTM coil was used. The MR-ZTE and CT images were compared in terms of subjective and objective image quality.
Results: Intrapulmonary structures were imaged using MRI-ZTE. Various nodules and masses, including micronodules, subsolid or ground glass opacification nodules, and various masses, were clearly visualized via MRI-ZTE. In terms of subjective image quality, there was no significant difference in lesion detectability between CT and MRI-ZTE (P = 0.8). In terms of objective image quality for MRI-ZTE, the SNRs and CNRs of the lung parenchyma, pulmonary nodules, trachea, peripheral bronchus, and peripheral pulmonary vessels were good.
Conclusions: MRI-ZTE enabled the detection of intrapulmonary structures and various pulmonary neoplasms with good image quality, including micronodules, subsolid or ground glass opacification nodules, and various masses. Therefore, MRI-ZTE has great potential as a nonradiation alternative to CT for the follow-up of pulmonary neoplasms.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235853 | PMC |
http://dx.doi.org/10.1186/s12880-025-01666-5 | DOI Listing |
JAMA Netw Open
September 2025
Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.
Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.
Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.
Langenbecks Arch Surg
September 2025
Department of Surgery HBP Unit, Simone Veil Hospital, University of Reims Champagne-Ardenne, Troyes, France.
Introduction: Pancreatic adenocarcinomas (PDAC) have a poor prognosis, with a 5-year relative Survival rate of 11.5%. Only 20% of patients are initially eligible for resection, and 50% of patients presented with metastatic disease, currently only candidates' palliative treatment.
View Article and Find Full Text PDFLung
September 2025
Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Introduction: Lactate has emerged as a multifunctional signaling molecule regulating various physiological and pathological processes. Furthermore, lactylation, a newly identified posttranslational modification triggered by lactate accumulation, plays significant roles in human health and diseases. This study aims to investigate the roles of lactate/lactylation in respiratory diseases.
View Article and Find Full Text PDFCancer
September 2025
Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Tobacco use is the primary contributor to disease and death in the United States, and cigarette smoking is the leading risk factor for lung cancer. Safe and effective treatments for tobacco dependence exist; however, access to and use of tobacco treatment remains low. The most recent Centers for Medicare and Medicaid Services National Coverage Determination requires a shared decision-making visit for lung cancer screening that includes counseling on the importance of maintaining cigarette smoking abstinence if a person formerly smoked; or the importance of smoking cessation if a person currently smokes and, if appropriate, furnishing of information about tobacco-cessation interventions.
View Article and Find Full Text PDFCancer Med
September 2025
Department of Pulmonary Medicine, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Background: The prognosis of small-cell lung cancer (SCLC) remains poor, particularly in patients with extensive-stage SCLC. The IMpower133 and CASPIAN trials revealed the efficacy of immune checkpoint inhibitors (ICIs) in extensive-stage SCLC patients with good performance status (PS). The aim of this study was to investigate the efficacy of ICIs in patients with poor PS.
View Article and Find Full Text PDF